AcrB-TolC efflux system is essential for macrolide resistance in Helicobacter pylori

Masaaki  Minami; Shin-nosuke  Hashikawa; Takafumi  Ando; Hidemi  Goto; Michio  Ohta

doi:10.30574/gscarr.2021.9.3.0292

Authors

Masaaki Minami Department of Bacteriology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Shin-nosuke Hashikawa Department of Molecular Bacteriology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takafumi Ando Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hidemi Goto Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Michio Ohta Department of Molecular Bacteriology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

DOI:

https://doi.org/10.30574/gscarr.2021.9.3.0292

Keywords:

Helicobacter pylori, AcrB, TolC, Macrolide, Drug resistant, Post antibiotic effect

Abstract

The prevalence of Helicobacter pylori strains resistant to macrolide is increasing worldwide. Macrolide molecules can be generally extruded by the AcrB-TolC system in bacteria. The H. pylori 26695 genome was assessed for putative translocases and the outer membrane efflux of AcrB (HP607) and TolC (HP605) proteins. We investigated the role of the AcrB-TolC efflux system in macrolide resistant (M-R) H. pylori. Both acrB- and tolC-mutant M-R strains were constructed from M-R strains by insertional inactivation of the acrB and tolC genes. The minimal inhibition concentrations (MICs) of erythromycin (EM) and clarithromycin (CLR) were determined by an agar dilution assay. To investigate the efflux ability of macrolides, intracellular accumulation of radiolabeled EM in the H. pylori 26695 strain, M-R strain, and acrB- and tolC-mutant M-R strains was measured by a liquid scintillation counter. For Post antibiotic effect (PAE), EM-treated H. pylori was diluted 1000-fold to remove antimicrobial activity. After additional 24 hours incubation, the CFU was measured. The decrease in the levels of resistance to EM and CLR was 32-fold higher for the acrB- and tolC-mutant M-R strains than the M-R strains. The intracellular EM concentration significantly increased in the acrB- and tolC-mutant M-R strains than the H. pylori 26695 and M-R strains. Diluted acrB, and tolC M-R mutant H. pylori after EM treatment was markedly reduced compared to M-R H. pylori. Our result showed that the M-R mechanism of H. pylori is significantly associated with AcrB-TolC efflux system

Metrics

Metrics Loading ...

References

Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin. Microbiol. Rev. 1997; 10: 720-741.

Sung JJY, Chung S, Ling TKW, Yung MY, Leung VKS, Ng EKW, Li MKK, Cheng AFB, Li AKC. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med. 1995; 332: 139-142.

Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325: 1127-1131.

Hiyama T, Tanaka S, Masuda H, Shima H, Kose K, Tuncel H, Ito M, Kitadai Y, Sumii M, Uemura N, Yoshihara M, Shimamoto F, Haruma K, Chayama K. Prevalence of Helicobacter pylori resistance to clarithromycin and metronidazole determined by 23S ribosomal RNA and rdxA gene analyses in Hiroshima, Japan. J Gastroenterol Hepatol. 2003; 18: 1202-1207.

Masuda H, Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Characteristics and trends of clarithromycin-resistant Helicobacter pylori isolates in Japan over a decade. Pathobiol. 2004; 71: 159-163.

Miyata E, Kudo T, Ikuse T, Tokita K, Arai N, Oka I, Kyodo R, Sato M, Hosoi K, Jimbo K, Aoyagi Y, Ohtsuka Y, Shimizu T. Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single-center study over 12 years. Helicobacter. 2021; 26: e12764.

O'Connor A, Furuta T, Gisbert JP, O'Morain C. Review - Treatment of Helicobacter pylori infection 2020. Helicobacter. 2020; 25 Suppl 1: e12743.

Paulsen IT, Chen J, Nelson KE, Saier Jr MH. Comparative genomics of microbial drug efflux systems. J Mol Microbiol Biotechnol. 2001; 3: 145-150.

Johnson JM, Church GM. Alignment and structure prediction of divergent protein families: periplasmic and outer membrane proteins of bacterial efflux pumps. J Mol Biol. 1999; 287: 695-715.

Koronakis V, Eswaran J, Hughes C. Structure and function of TolC: the bacterial exit duct for proteins and drugs. Annu Rev Biochem. 2004; 73: 467-89.

Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997; 388: 539-547.

Bina JE, Alm RA, Uria-Nickelsen M, Thomas SR, Trust TJ, Hancock RE. Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob Agents Chemother. 2000; 44: 248-54.

Hassan IJ, Stark RM, Greenman J, Millar MR. Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637. J Antimicrob Chemother. 1998; 42: 661-663.

Ando T, Israel DA, Kusugami K, Blaser MJ. HP0333, a member of the dprA family, is involved in natural transformation in Helicobacter pylori. J Bacteriol. 1999; 181: 5572–5580.

Minami M, Ando T, Hashikawa SN, Torii K, Hasegawa T, Israel DA, Ina K, Kusugami K, Goto H, Ohta M. Effect of glycine on Helicobacter pylori in vitro. Antimicrob Agents Chemother. 2004; 48: 3782-3788.

NCCLS. Performance standards for antimicrobial susceptibility testing: M100-S13. 2003.

Sánchez L, Pan W, Viñas M, Nikaido H. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J Bacteriol. 1997; 179: 6855-6857.

Trepod CM, Mott JE. Identification of the Haemophilus influenzae tolC gene by susceptibility profiles of insertionally inactivated efflux pump mutants. Antimicrob Agents Chemother. 2004; 48: 1416-1418.

Koronakis V. TolC-the bacterial exit duct for proteins and drugs. FEBS Lett. 2003; 555: 66-71.

Augustus AM, Celaya T, Husain F, Humbard M, Misra R. Antibiotic-sensitive TolC mutants and their suppressors. J Bacteriol. 2004; 186: 1851-1860.

Odenholt I, Löwdin E, Cars O. Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase. Antimicrob Agents Chemother. 1997; 41: 2522-2526.

Majcherczyk PA. The issue of the true postantibiotic effect. J Antimicrob Chemother. 1996; 37: 188–189.